APO Research
Talk to an analyst

APO RESEARCH · REPORT

C-MET & HGF Inhibitors

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

Selected research

Market Outlook & Growth Opportunities

Global C-MET & HGF Inhibitors Market Outlook and Growth Opportunities 2026

28 December 2025201 pages

Choose your research edition.

Industry ResearchC-MET & HGF Inhibitors Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal C-MET & HGF Inhibitors Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal C-MET & HGF Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal C-MET & HGF Inhibitors Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal C-MET & HGF Inhibitors Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.

C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.

Read the full market overview

North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.

Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.

This report provides an overview of the global C-MET & HGF Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of C-MET & HGF Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents C-MET & HGF Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the C-MET & HGF Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

C-MET & HGF Inhibitors Segment by Company

Exelixis

Ipsen

Pfizer

Novartis

Takeda

Merck KGaA

Merck

Daiichi Sankyo

GSK

Bristol-Myers Squibb(BMS)

Roche

AVEO Pharmaceuticals

Amgen

AstraZeneca

Mirati Therapeutics

Eli Lilly

Johnson & Johnson

Eisai

Hutchison MediPharma

Kringle Pharmaceuticals

C-MET & HGF Inhibitors Segment by Type

Cabozantinib

Crizotinib

Others

C-MET & HGF Inhibitors Segment by Application

Hospital

Drug Store

C-MET & HGF Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global C-MET & HGF Inhibitors status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions C-MET & HGF Inhibitors market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify C-MET & HGF Inhibitors significant trends, drivers, influence factors in global and regions.

6. To analyze C-MET & HGF Inhibitors competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C-MET & HGF Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of C-MET & HGF Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C-MET & HGF Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the C-MET & HGF Inhibitors market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global C-MET & HGF Inhibitors industry.

Chapter 3: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of C-MET & HGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of C-MET & HGF Inhibitors in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. C-MET & HGF Inhibitors Industry Trends Table 2. C-MET & HGF Inhibitors Industry Drivers Table 3. C-MET & HGF Inhibitors Industry Opportunities and Challenges Table 4. C-MET & HGF Inhibitors Industry Restraints Table 5. Global C-MET & HGF Inhibitors Revenue by Company (US$ Million) & (2021-2026) Table 6. Global C-MET & HGF Inhibitors Revenue Share by Company (2021-2026) Table 7. Global C-MET & HGF Inhibitors Sales Volume by Company (K Units) & (2021-2026) Table 8. Global C-MET & HGF Inhibitors Sales Volume Share by Company (2021-2026) Table 9. Global C-MET & HGF Inhibitors Average Price (US$/Unit) of Company (2021-2026) Table 10. Global C-MET & HGF Inhibitors Company Ranking, (2024-2026) & (USD Million) Table 11. Global C-MET & HGF Inhibitors Key Company Manufacturing Base & Headquarters Table 12. Global C-MET & HGF Inhibitors Company, Product Type & Application Table 13. Global C-MET & HGF Inhibitors Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global C-MET & HGF Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cabozantinib Table 18. Significant Companies of Crizotinib Table 19. Significant Companies of Others Table 20. Global C-MET & HGF Inhibitors Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global C-MET & HGF Inhibitors Sales Volume by Type (2021-2026) & (K Units) Table 22. Global C-MET & HGF Inhibitors Sales Volume by Type (2027-2032) & (K Units) Table 23. Global C-MET & HGF Inhibitors Sales Volume Share by Type (2021-2026) Table 24. Global C-MET & HGF Inhibitors Sales Volume Share by Type (2027-2032) Table 25. Global C-MET & HGF Inhibitors Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global C-MET & HGF Inhibitors Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global C-MET & HGF Inhibitors Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global C-MET & HGF Inhibitors Sales Value Share by Type (2021-2026) Table 29. Global C-MET & HGF Inhibitors Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Drug Store Table 32. Global C-MET & HGF Inhibitors Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global C-MET & HGF Inhibitors Sales Volume by Application (2021-2026) & (K Units) Table 34. Global C-MET & HGF Inhibitors Sales Volume by Application (2027-2032) & (K Units) Table 35. Global C-MET & HGF Inhibitors Sales Volume Share by Application (2021-2026) Table 36. Global C-MET & HGF Inhibitors Sales Volume Share by Application (2027-2032) Table 37. Global C-MET & HGF Inhibitors Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global C-MET & HGF Inhibitors Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global C-MET & HGF Inhibitors Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global C-MET & HGF Inhibitors Sales Value Share by Application (2021-2026) Table 41. Global C-MET & HGF Inhibitors Sales Value Share by Application (2027-2032) Table 42. Global C-MET & HGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global C-MET & HGF Inhibitors Sales by Region (2021-2026) & (K Units) Table 44. Global C-MET & HGF Inhibitors Sales Market Share by Region (2021-2026) Table 45. Global C-MET & HGF Inhibitors Sales by Region (2027-2032) & (K Units) Table 46. Global C-MET & HGF Inhibitors Sales Market Share by Region (2027-2032) Table 47. Global C-MET & HGF Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global C-MET & HGF Inhibitors Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global C-MET & HGF Inhibitors Sales Value Share by Region (2021-2026) Table 50. Global C-MET & HGF Inhibitors Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global C-MET & HGF Inhibitors Sales Value Share by Region (2027-2032) Table 52. Global C-MET & HGF Inhibitors Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global C-MET & HGF Inhibitors Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global C-MET & HGF Inhibitors Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global C-MET & HGF Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 57. Global C-MET & HGF Inhibitors Sales Market Share by Country (2021-2026) Table 58. Global C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 59. Global C-MET & HGF Inhibitors Sales Market Share by Country (2027-2032) Table 60. Global C-MET & HGF Inhibitors Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global C-MET & HGF Inhibitors Sales Value Market Share by Country (2021-2026) Table 62. Global C-MET & HGF Inhibitors Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global C-MET & HGF Inhibitors Sales Value Market Share by Country (2027-2032) Table 64. Exelixis Company Information Table 65. Exelixis Business Overview Table 66. Exelixis C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Exelixis C-MET & HGF Inhibitors Product Portfolio Table 68. Exelixis Recent Development Table 69. Ipsen Company Information Table 70. Ipsen Business Overview Table 71. Ipsen C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Ipsen C-MET & HGF Inhibitors Product Portfolio Table 73. Ipsen Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Pfizer C-MET & HGF Inhibitors Product Portfolio Table 78. Pfizer Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Novartis C-MET & HGF Inhibitors Product Portfolio Table 83. Novartis Recent Development Table 84. Takeda Company Information Table 85. Takeda Business Overview Table 86. Takeda C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Takeda C-MET & HGF Inhibitors Product Portfolio Table 88. Takeda Recent Development Table 89. Merck KGaA Company Information Table 90. Merck KGaA Business Overview Table 91. Merck KGaA C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Merck KGaA C-MET & HGF Inhibitors Product Portfolio Table 93. Merck KGaA Recent Development Table 94. Merck Company Information Table 95. Merck Business Overview Table 96. Merck C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Merck C-MET & HGF Inhibitors Product Portfolio Table 98. Merck Recent Development Table 99. Daiichi Sankyo Company Information Table 100. Daiichi Sankyo Business Overview Table 101. Daiichi Sankyo C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio Table 103. Daiichi Sankyo Recent Development Table 104. GSK Company Information Table 105. GSK Business Overview Table 106. GSK C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. GSK C-MET & HGF Inhibitors Product Portfolio Table 108. GSK Recent Development Table 109. Bristol-Myers Squibb(BMS) Company Information Table 110. Bristol-Myers Squibb(BMS) Business Overview Table 111. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio Table 113. Bristol-Myers Squibb(BMS) Recent Development Table 114. Roche Company Information Table 115. Roche Business Overview Table 116. Roche C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Roche C-MET & HGF Inhibitors Product Portfolio Table 118. Roche Recent Development Table 119. AVEO Pharmaceuticals Company Information Table 120. AVEO Pharmaceuticals Business Overview Table 121. AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio Table 123. AVEO Pharmaceuticals Recent Development Table 124. Amgen Company Information Table 125. Amgen Business Overview Table 126. Amgen C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Amgen C-MET & HGF Inhibitors Product Portfolio Table 128. Amgen Recent Development Table 129. AstraZeneca Company Information Table 130. AstraZeneca Business Overview Table 131. AstraZeneca C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. AstraZeneca C-MET & HGF Inhibitors Product Portfolio Table 133. AstraZeneca Recent Development Table 134. Mirati Therapeutics Company Information Table 135. Mirati Therapeutics Business Overview Table 136. Mirati Therapeutics C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio Table 138. Mirati Therapeutics Recent Development Table 139. Eli Lilly Company Information Table 140. Eli Lilly Business Overview Table 141. Eli Lilly C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Eli Lilly C-MET & HGF Inhibitors Product Portfolio Table 143. Eli Lilly Recent Development Table 144. Johnson & Johnson Company Information Table 145. Johnson & Johnson Business Overview Table 146. Johnson & Johnson C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio Table 148. Johnson & Johnson Recent Development Table 149. Eisai Company Information Table 150. Eisai Business Overview Table 151. Eisai C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Eisai C-MET & HGF Inhibitors Product Portfolio Table 153. Eisai Recent Development Table 154. Hutchison MediPharma Company Information Table 155. Hutchison MediPharma Business Overview Table 156. Hutchison MediPharma C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio Table 158. Hutchison MediPharma Recent Development Table 159. Kringle Pharmaceuticals Company Information Table 160. Kringle Pharmaceuticals Business Overview Table 161. Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio Table 163. Kringle Pharmaceuticals Recent Development Table 164. Key Raw Materials Table 165. Raw Materials Key Suppliers Table 166. C-MET & HGF Inhibitors Distributors List Table 167. C-MET & HGF Inhibitors Customers List Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. C-MET & HGF Inhibitors Product Image Figure 2. Global C-MET & HGF Inhibitors Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global C-MET & HGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 4. Global C-MET & HGF Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global C-MET & HGF Inhibitors Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global C-MET & HGF Inhibitors Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cabozantinib Image Figure 10. Crizotinib Image Figure 11. Others Image Figure 12. Global C-MET & HGF Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global C-MET & HGF Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global C-MET & HGF Inhibitors Sales Volume Share by Type (2021-2032) Figure 15. Global C-MET & HGF Inhibitors Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global C-MET & HGF Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global C-MET & HGF Inhibitors Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Drug Store Image Figure 20. Global C-MET & HGF Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global C-MET & HGF Inhibitors Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global C-MET & HGF Inhibitors Sales Volume Share by Application (2021-2032) Figure 23. Global C-MET & HGF Inhibitors Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global C-MET & HGF Inhibitors Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global C-MET & HGF Inhibitors Sales Value Share by Application (2021-2032) Figure 26. Global C-MET & HGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global C-MET & HGF Inhibitors Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global C-MET & HGF Inhibitors Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global C-MET & HGF Inhibitors Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America C-MET & HGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 31. North America C-MET & HGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe C-MET & HGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 33. Europe C-MET & HGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific C-MET & HGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific C-MET & HGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America C-MET & HGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 37. South America C-MET & HGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa C-MET & HGF Inhibitors Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa C-MET & HGF Inhibitors Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. C-MET & HGF Inhibitors Value Chain Figure 125. Manufacturing Cost Structure Figure 126. C-MET & HGF Inhibitors Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Cabozantinib
  • Crizotinib
  • Others
Applications
  • Hospital
  • Drug Store
Companies covered
  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Merck
  • Daiichi Sankyo
  • GSK
  • Bristol-Myers Squibb(BMS)
  • Roche
  • AVEO Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Mirati Therapeutics
  • Eli Lilly
  • Johnson & Johnson
  • Eisai
  • Hutchison MediPharma
  • Kringle Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global C-MET & HGF Inhibitors Sales Value (2021-2032)
  4. 1.2.2 Global C-MET & HGF Inhibitors Sales Volume (2021-2032)
  5. 1.2.3 Global C-MET & HGF Inhibitors Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 C-MET & HGF Inhibitors Market Dynamics
  1. 2.1 C-MET & HGF Inhibitors Industry Trends
  2. 2.2 C-MET & HGF Inhibitors Industry Drivers
  3. 2.3 C-MET & HGF Inhibitors Industry Opportunities and Challenges
  4. 2.4 C-MET & HGF Inhibitors Industry Restraints
3 C-MET & HGF Inhibitors Market by Company
  1. 3.1 Global C-MET & HGF Inhibitors Company Revenue Ranking in 2025
  2. 3.2 Global C-MET & HGF Inhibitors Revenue by Company (2021-2026)
  3. 3.3 Global C-MET & HGF Inhibitors Sales Volume by Company (2021-2026)
  4. 3.4 Global C-MET & HGF Inhibitors Average Price by Company (2021-2026)
  5. 3.5 Global C-MET & HGF Inhibitors Company Ranking (2024-2026)
  6. 3.6 Global C-MET & HGF Inhibitors Company Manufacturing Base and Headquarters
  7. 3.7 Global C-MET & HGF Inhibitors Company Product Type and Application
  8. 3.8 Global C-MET & HGF Inhibitors Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global C-MET & HGF Inhibitors Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 C-MET & HGF Inhibitors Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 C-MET & HGF Inhibitors Market by Type
  1. 4.1 C-MET & HGF Inhibitors Type Introduction
  2. 4.1.1 Cabozantinib
  3. 4.1.2 Crizotinib
  4. 4.1.3 Others
  5. 4.2 Global C-MET & HGF Inhibitors Sales Volume by Type
  6. 4.2.1 Global C-MET & HGF Inhibitors Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global C-MET & HGF Inhibitors Sales Volume by Type (2021-2032)
  8. 4.2.3 Global C-MET & HGF Inhibitors Sales Volume Share by Type (2021-2032)
  9. 4.3 Global C-MET & HGF Inhibitors Sales Value by Type
  10. 4.3.1 Global C-MET & HGF Inhibitors Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global C-MET & HGF Inhibitors Sales Value by Type (2021-2032)
  12. 4.3.3 Global C-MET & HGF Inhibitors Sales Value Share by Type (2021-2032)
5 C-MET & HGF Inhibitors Market by Application
  1. 5.1 C-MET & HGF Inhibitors Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug Store
  4. 5.2 Global C-MET & HGF Inhibitors Sales Volume by Application
  5. 5.2.1 Global C-MET & HGF Inhibitors Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global C-MET & HGF Inhibitors Sales Volume by Application (2021-2032)
  7. 5.2.3 Global C-MET & HGF Inhibitors Sales Volume Share by Application (2021-2032)
  8. 5.3 Global C-MET & HGF Inhibitors Sales Value by Application
  9. 5.3.1 Global C-MET & HGF Inhibitors Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global C-MET & HGF Inhibitors Sales Value by Application (2021-2032)
  11. 5.3.3 Global C-MET & HGF Inhibitors Sales Value Share by Application (2021-2032)
6 C-MET & HGF Inhibitors Regional Sales and Value Analysis
  1. 6.1 Global C-MET & HGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global C-MET & HGF Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global C-MET & HGF Inhibitors Sales by Region: 2021-2026
  4. 6.2.2 Global C-MET & HGF Inhibitors Sales by Region (2027-2032)
  5. 6.3 Global C-MET & HGF Inhibitors Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global C-MET & HGF Inhibitors Sales Value by Region (2021-2032)
  7. 6.4.1 Global C-MET & HGF Inhibitors Sales Value by Region: 2021-2026
  8. 6.4.2 Global C-MET & HGF Inhibitors Sales Value by Region (2027-2032)
  9. 6.5 Global C-MET & HGF Inhibitors Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America C-MET & HGF Inhibitors Sales Value (2021-2032)
  12. 6.6.2 North America C-MET & HGF Inhibitors Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe C-MET & HGF Inhibitors Sales Value (2021-2032)
  15. 6.7.2 Europe C-MET & HGF Inhibitors Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific C-MET & HGF Inhibitors Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific C-MET & HGF Inhibitors Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America C-MET & HGF Inhibitors Sales Value (2021-2032)
  21. 6.9.2 South America C-MET & HGF Inhibitors Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa C-MET & HGF Inhibitors Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa C-MET & HGF Inhibitors Sales Value Share by Country, 2025 VS 2032
7 C-MET & HGF Inhibitors Country-level Sales and Value Analysis
  1. 7.1 Global C-MET & HGF Inhibitors Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global C-MET & HGF Inhibitors Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global C-MET & HGF Inhibitors Sales by Country (2021-2032)
  4. 7.3.1 Global C-MET & HGF Inhibitors Sales by Country (2021-2026)
  5. 7.3.2 Global C-MET & HGF Inhibitors Sales by Country (2027-2032)
  6. 7.4 Global C-MET & HGF Inhibitors Sales Value by Country (2021-2032)
  7. 7.4.1 Global C-MET & HGF Inhibitors Sales Value by Country (2021-2026)
  8. 7.4.2 Global C-MET & HGF Inhibitors Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt C-MET & HGF Inhibitors Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt C-MET & HGF Inhibitors Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt C-MET & HGF Inhibitors Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Exelixis
  2. 8.1.1 Exelixis Company Information
  3. 8.1.2 Exelixis Business Overview
  4. 8.1.3 Exelixis C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Exelixis C-MET & HGF Inhibitors Product Portfolio
  6. 8.1.5 Exelixis Recent Developments
  7. 8.2 Ipsen
  8. 8.2.1 Ipsen Company Information
  9. 8.2.2 Ipsen Business Overview
  10. 8.2.3 Ipsen C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Ipsen C-MET & HGF Inhibitors Product Portfolio
  12. 8.2.5 Ipsen Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer C-MET & HGF Inhibitors Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis C-MET & HGF Inhibitors Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Takeda
  26. 8.5.1 Takeda Company Information
  27. 8.5.2 Takeda Business Overview
  28. 8.5.3 Takeda C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Takeda C-MET & HGF Inhibitors Product Portfolio
  30. 8.5.5 Takeda Recent Developments
  31. 8.6 Merck KGaA
  32. 8.6.1 Merck KGaA Company Information
  33. 8.6.2 Merck KGaA Business Overview
  34. 8.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck KGaA C-MET & HGF Inhibitors Product Portfolio
  36. 8.6.5 Merck KGaA Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Merck C-MET & HGF Inhibitors Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 GSK
  50. 8.9.1 GSK Company Information
  51. 8.9.2 GSK Business Overview
  52. 8.9.3 GSK C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 GSK C-MET & HGF Inhibitors Product Portfolio
  54. 8.9.5 GSK Recent Developments
  55. 8.10 Bristol-Myers Squibb(BMS)
  56. 8.10.1 Bristol-Myers Squibb(BMS) Company Information
  57. 8.10.2 Bristol-Myers Squibb(BMS) Business Overview
  58. 8.10.3 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb(BMS) Recent Developments
  61. 8.11 Roche
  62. 8.11.1 Roche Company Information
  63. 8.11.2 Roche Business Overview
  64. 8.11.3 Roche C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Roche C-MET & HGF Inhibitors Product Portfolio
  66. 8.11.5 Roche Recent Developments
  67. 8.12 AVEO Pharmaceuticals
  68. 8.12.1 AVEO Pharmaceuticals Company Information
  69. 8.12.2 AVEO Pharmaceuticals Business Overview
  70. 8.12.3 AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
  72. 8.12.5 AVEO Pharmaceuticals Recent Developments
  73. 8.13 Amgen
  74. 8.13.1 Amgen Company Information
  75. 8.13.2 Amgen Business Overview
  76. 8.13.3 Amgen C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Amgen C-MET & HGF Inhibitors Product Portfolio
  78. 8.13.5 Amgen Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca C-MET & HGF Inhibitors Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Mirati Therapeutics
  86. 8.15.1 Mirati Therapeutics Company Information
  87. 8.15.2 Mirati Therapeutics Business Overview
  88. 8.15.3 Mirati Therapeutics C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio
  90. 8.15.5 Mirati Therapeutics Recent Developments
  91. 8.16 Eli Lilly
  92. 8.16.1 Eli Lilly Company Information
  93. 8.16.2 Eli Lilly Business Overview
  94. 8.16.3 Eli Lilly C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Eli Lilly C-MET & HGF Inhibitors Product Portfolio
  96. 8.16.5 Eli Lilly Recent Developments
  97. 8.17 Johnson & Johnson
  98. 8.17.1 Johnson & Johnson Company Information
  99. 8.17.2 Johnson & Johnson Business Overview
  100. 8.17.3 Johnson & Johnson C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio
  102. 8.17.5 Johnson & Johnson Recent Developments
  103. 8.18 Eisai
  104. 8.18.1 Eisai Company Information
  105. 8.18.2 Eisai Business Overview
  106. 8.18.3 Eisai C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Eisai C-MET & HGF Inhibitors Product Portfolio
  108. 8.18.5 Eisai Recent Developments
  109. 8.19 Hutchison MediPharma
  110. 8.19.1 Hutchison MediPharma Company Information
  111. 8.19.2 Hutchison MediPharma Business Overview
  112. 8.19.3 Hutchison MediPharma C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio
  114. 8.19.5 Hutchison MediPharma Recent Developments
  115. 8.20 Kringle Pharmaceuticals
  116. 8.20.1 Kringle Pharmaceuticals Company Information
  117. 8.20.2 Kringle Pharmaceuticals Business Overview
  118. 8.20.3 Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
  120. 8.20.5 Kringle Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 C-MET & HGF Inhibitors Value Chain Analysis
  2. 9.1.1 C-MET & HGF Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 C-MET & HGF Inhibitors Sales Mode & Process
  6. 9.2 C-MET & HGF Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 C-MET & HGF Inhibitors Distributors
  9. 9.2.3 C-MET & HGF Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst